abstract Traumatic brain injury (TBI) is a multifaceted disease with intrinsically complex heterogeneity and remains a significant clinical challenge to manage. TBI model systems have demonstrated many mechanisms that contribute to brain parenchymal cell death, including glutamate and calcium toxicity, oxidative stress, inflammation, and mitochondrial dysfunction. Mitochondria are critically regulated by uncoupling proteins (UCP), which allow protons to leak back into the matrix and thus reduce the mitochondrial membrane potential by dissipating the proton motive force. This uncoupling of oxidative phosphorylation from adenosine triphosphate (ATP) synthesis is potentially critical for protection against cellular injury as a result of TBI and stroke. A greater understanding of the underlying mechanism or mechanisms by which uncoupling protein-2 (UCP2) functions to maintain or optimize mitochondrial function, and the conditions which precipitate the failure of these mechanisms, would inform future research and treatment strategies. We posit that UCP2-mediated function underlies the physiological response to neuronal stress associated with traumatic and ischemic injury and that clinical development of UCP2-targeted treatment would significantly impact these patient populations. With a focus on clinical relevance in TBI, we synthesize current knowledge concerning UCP2 and its potential neuroprotective role and apply this body of knowledge to current and potential treatment modalities.
through electron shuttling and a proton motive force (PMF) across the inner mitochondrial membrane. These gradient forces consist of a chemical potential and, more critically, an electrical potential (ΔΨ m ), which accounts for 90% of the PMF [9] [10] [11] [12] . This ΔΨ m is the potential energy source that drives phosphorylation of adenosine diphosphate (ADP) to ATP by allowing hydrogen ions to move down their energy gradient through ATP synthase, but is also the source of potentially dangerous reactive oxygen species (ROS) [13, 14] . In the instance of TBI and stroke, ΔΨ m is too great, resulting in calcium flows into mitochondria with concurrent production of ROS and subsequent cellular damage, thus initiating the process of cell death.
This process occurs through the direct result of the ΔΨ m increase triggering the mitochondrial pore transition protein (mPTP) complex [15] [16] [17] [18] . An alternative pathway capable of dissipating
physiology of ucp2
Oxidative phosphorylation UCP dissociate oxidation from phosphorylation, suppressing ATP production per mitochondrion under physiological conditions. During normal cellular function this bypassing of ATP synthase would result in a dangerous and wasteful futile cycle, but under conditions in which ATP production is limited due to lack of necessary substrates, including oxygen, the dissipation of ΔΨ m through other means would be necessary to protect against ROS damage and initiation of apoptosis [19, 40, 41] . Experimental data suggest that UCP2 contributes to neuronal stress tolerance in acute settings, which over time triggers mitochondrial proliferation and increased ATP/ADP production [32, 42] . As ΔΨ m is intimately linked to ATP production, a disruption of delivery or ability to effectively utilize substrates for oxidative phosphorylation would lead to ΔΨ m increasing to dangerous levels with subsequent ROS production, calcium influx into mitochondria and eventually cell death [39, 40, [43] [44] [45] . Recent evidence further indicates that the principle function of UCP2 is to dissipate ΔΨ m in vivo [46] , which may underlie the emerging neuroprotective role of UCP2 in TBI.
Calcium regulation and apoptosis
Mitochondria represent a point of integration for cell death signaling in vertebrates through the activation of mitochondrial membrane permeabilization [1, 40, 44, 47, 48] , releasing myriad cell death factors associated with apoptosis, necrosis, or the recently described hybrid necroptosis [45] , and host both prosurvival and pro-apoptotic factors critical for regulating mitochondrial membrane permeability [49] . Regulation of calcium, particularly the shifting of calcium load into mitochondria, is intimately linked to both the necrotic and apoptotic cell death pathways [45, 50] . UCP2 has been identified as a regulator of calcium homeostasis, whose role is best appreciated in cases of cellular stress [51, 52] .
Calcium influx into mitochondria increases with a greater ΔΨ m , as does ROS production [19, 41] . Thus UCP2 overexpression resulted in decreased ΔΨ m restricting calcium influx into mitochondria and decreased ROS production [39, 43] . The activation of and interaction between several mitochondrial channels, including calcium channels, activated directly or indirectly through mitochondrial ΔΨ m , changes under the control of UCP2 and emphasizes the importance of the uncoupler [40, 44, 48] .
Reactive oxygen species (ROS)
Reactive oxygen species (ROS), both radicals and non-radicals (hydrogen peroxide), are highly reactive byproducts of oxidative respiration present in all cells that function as signaling elements at physiological concentrations [19, 53] . Mitochondrial ROS production is highly sensitive to slight changes in ΔΨ m [54] [55] [56] . UCP2 lowers ΔΨ m with the subsequent decrease of ROS production [38, 42, 57, 58] ; conversely, in UCP2 knockout animals, an increase in ΔΨ m is observed, which promotes ROS production [42, 59] . Interestingly, UCP2 also serves as a cellular target of ROS signals such as superoxide, which activates UCP2 to reduce ΔΨ m and lower ROS generation [60] . Recent evidence further supports the notion that rising levels of ROS induce mitochondrial uncoupling through UCP2 activation, a process which also liberates glutathione [27] , indicating that under physiological conditions UCP2 is part of an adaptive response to maintain proper redox homeostasis through bidirectional regulation.
Physiological compensation
The physiological role of UCP2 is thus one of compensations to decrease ΔΨ m in the face of cellular stress. UCP2 is central to the diabetes-related stress response of pancreatic islet cells and has been used as a marker of sublethal insult to beta cells [61, 62] , eventually resulting in activation of the mPTP [63] . This shift from effective compensation to mPTP activation and decompensation may underlie recent observations that the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist rosiglitazone, known to cause oxidative damage to cardiomyocytes, has an acute protective effect in cultured cells [14] and neurons [64] . In the case of TBI, the role of UCP2 would be of acute compensation, potentially mitigating damage enough to allow cellular recovery in cases where UCP2 is not overwhelmed. Exemplifying this mechanism is ghrelin, which has been shown to be neuroprotective in the context of TBI through a mechanism reminiscent of ischemic preconditioning, resulting in increased UCP2 expression and greater neuroprotection [7, 8, 65, 66] . In contrast, ghrelin's counterpart leptin has been shown to have more acute UCP2-dependent mitochondrial stabilization effects in thalamic neurons [64, 67] . It appears that in neurons, UCP2 stabilizes mitochondria by responding to sublethal stress.
pathophysiology of ucp2
Neurodegeneration ROS, particularly hydrogen peroxide, have come to be appreciated as important for Amyloid-β is recognized as a part of Alzheimer's disease pathophysiology. While neuroprotective in the initial phase [76] , its accumulation is damaging and not unique to Alzheimer's disease alone: amyloid-β has also been found to accumulate in TBI patients [77] [78] [79] . Oxidative stress in the context of TBI was demonstrated to increase production of amyloid in the brain. In controlled studies of TBI, it was found that levels of ROS were elevated within one hour after injury and persisted at elevated levels for more than 4 days [80] . One recent study identified ursocholanic acid as a compound which acted to recover mitochondrial function and normalize ATP levels in fibroblasts from patients with a parkin (PARK2) mutation [82] . Importantly, the cell donors were patients with a predisposition to a Parkinson diagnosis, not those with diagnosed
Parkinson's disease. The most attractive feature of such approaches to finding novel treatments of neurodegenerative disease is the recognition that the optimal time to treat is during the subclinical compensatory phase, before failure of the system allows diagnosis.
Reperfusion injury and UCP2
Post-traumatic oxygen delivery is an important part of emergent therapy to prevent complications of TBI, such that hyperbaric oxygen has been studied alongside high-flow nasal cannula to optimize oxygen delivery to brain parenchyma without inducing oxygen toxicity. Both 60-min bursts of hyperbaric oxygen and three-hour treatments with high-flow nasal cannula were shown to be efficacious, increasing cerebral blood flow and decreasing lactate levels with no sign of pulmonary or cerebral damage in patients with severe TBI [83] . Murine hyperoxia has been shown to induce UCP2 within 60 min, perhaps in response to the sudden increase in ROS production, suggesting a mechanism for this protection in which UCP2 was not being transcribed anew but that existing UCP2 mRNA and glutathione-coupled UCP2 were being mobilized; indeed, UCP2 protein level was found to increase with a corresponding decrease in ΔΨ m while the amount of UCP2 mRNA did not change [84] . This result extends specifically to toxicity mediated by hyperactivity associated with seizure in a murine model and is postulated to be at the core of the preconditioning phenomenon of cerebral vascular injury protection [32] . Oxygen delivery is universally recognized as critically important to the preservation of function in cerebral injury, but is also perhaps only important given the assumed preservation of the ability of cerebral parenchyma to utilize the oxygen with functioning mitochondria [85] .
We hypothesize that UCP2 is of universal importance for helping cells overcome periods of stress. UCP2 is also part of the decisionmaking machinery that pivots the cell from UCP2 induction has been found to be protective against ischemia-reperfusion injury and may be a common downstream factor in multiple pathways including ischemic preconditioning protection in human neurons [64] . In contrast to UCP1, UCP2 does not contribute to core body thermogenesis; however, intrinsic to its ability to uncouple oxidative phosphorylation, UCP2 dissipates energy in the form of heat at the mitochondrial level. Because neurotransmission is highly temperature sensitive [89, 90] and neuronal UCP2-containing mitochondria appear to accumulate in axon terminals [29] , experimental data suggest that UCP2 may function to generate a synaptic microenvironmental Translational Neuroscience temperature gradient and thermally modulate neurotransmission [29, 91] . The temperaturedependent nature of neurotransmitter diffusion and receptor kinetics has been well established [92, 93] . Recent evidence further supports that both synaptic and volume diffusion of neurotransmitters are highly temperature sensitive [89, 90] . Further, neurotransmission is highly sensitive to cellular mechanisms that regulate calcium and ROS homeostasis [50, 71, 94] .
Traumatic brain injury (Tbi)
The effects of TBI on brain metabolism may also Hypothermia seeks to decrease ROS production by decreasing energy demand, but has significant issues in terms of methods applied to achieve cooling [101, 102] . With a greater understanding of the metabolic pathways responsible for the reduced ROSassociated cellular damage as a result of cooling, one could pharmacologically target those pathways and allow rapid and effective prehospital or in-hospital cooling effects without dependence on ambulance travel times or comorbidities such as chronic heart failure that may preclude some cooling strategies [101] .
Given that UCP2 would dissipate ΔΨ m through heat generation and release, some manner of cooling would likely remain necessary but it is possible that the target temperatures may be significantly closer to normal body temperature given the targeted nature of such a therapy. The key to the attractiveness of a UCP2 activation approach to cooling is that as excess ΔΨ m dissipates and the danger of ROSmediated damage is reduced, the substrate for UCP2-generated heat would also be reduced in real time, offering not only a tunable property in ΔΨ m response to such a therapy but also a prognostic indicator in the form of clinically measureable temperature changes.
conclusion
Early intervention to prevent initial neuronal injury extension after TBI is critical for TBI recovery, and UCP2 may offer an important target of early treatment. The efficient delivery of oxygen and glucose to neural tissues after injury has been emphasized [83, 103] , but the usefulness of these depends upon the retention of cellular ability to process and utilize them [85] . Post-injury mitochondrial uncoupling can increase tissue salvaged and cognition retained in model systems [104] and may be at least as important as maintaining oxygenation in ischemic neural tissue [85] .
While the pleotropic effects of hypothermia have been shown to be efficacious [105] and may include the preservation of mitochondrial function [106] , the targeting of UCP2 may provide a specific and reliable treatment for TBI patients to minimize injury and maximize recovery. New techniques are emerging at both the subcellular level [53] and the tissue level [107] to understand the processes underlying TBI, and the development of new techniques to more specifically prevent damage to brain parenchyma will undoubtedly result in improved patient outcomes. 
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